Human leukocyte antigen class I (HLA-I) molecules are encoded by major histocompatibility
complex (MHC) class I loci in humans. The binding and interaction between HLA-I …

Antigen presentation lies at the heart of immune recognition of infected or malignant cells.
For this reason, important efforts have been made to predict which peptides are more likely …

Major histocompatibility complex (MHC) molecules are expressed on the cell surface, where
they present peptides to T cells, which gives them a key role in the development of T-cell …

Major histocompatibility complex II (MHC II) molecules play a vital role in the onset and
control of cellular immunity. In a highly selective process, MHC II presents peptides derived …

Increasing evidence indicates CD4+ T cells can recognize cancer-specific antigens and
control tumor growth. However, it remains difficult to predict the antigens that will be …

HLA-I molecules bind short peptides and present them for recognition by CD8+ T cells. The
length of HLA-I ligands typically ranges from 8 to 12 aa, but variability is observed across …

Human leukocyte antigen (HLA) class II antigen presentation is key for controlling and
triggering T cell immune responses. HLA-DQ molecules, which are believed to play a major …

Mass spectrometry (MS) based immunopeptidomics is used in several biomedical
applications including neo-epitope discovery in oncology, next-generation vaccine …

The set of peptides presented on a cell's surface by MHC molecules is known as the
immunopeptidome. Current mass spectrometry technologies allow for identification of large …

The science that investigates the ensembles of all peptides associated to human leukocyte
antigen (HLA) molecules is termed" immunopeptidomics" and is typically driven by mass …